Management of low-grade cervical cytology in young women: Cohort study from Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Management of low-grade cervical cytology in young women : Cohort study from Denmark. / St-Martin, Gry; Thamsborg, Lise Holst; Andersen, Berit; Christensen, Jette; Ejersbo, Dorthe; Jochumsen, Kirsten; Johansen, Tonje; Larsen, Lise Grupe; Waldstrøm, Marianne; Lynge, Elsebeth.

In: Acta Oncologica, Vol. 60, No. 4, 2021, p. 444-451.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

St-Martin, G, Thamsborg, LH, Andersen, B, Christensen, J, Ejersbo, D, Jochumsen, K, Johansen, T, Larsen, LG, Waldstrøm, M & Lynge, E 2021, 'Management of low-grade cervical cytology in young women: Cohort study from Denmark', Acta Oncologica, vol. 60, no. 4, pp. 444-451. https://doi.org/10.1080/0284186X.2020.1831061

APA

St-Martin, G., Thamsborg, L. H., Andersen, B., Christensen, J., Ejersbo, D., Jochumsen, K., Johansen, T., Larsen, L. G., Waldstrøm, M., & Lynge, E. (2021). Management of low-grade cervical cytology in young women: Cohort study from Denmark. Acta Oncologica, 60(4), 444-451. https://doi.org/10.1080/0284186X.2020.1831061

Vancouver

St-Martin G, Thamsborg LH, Andersen B, Christensen J, Ejersbo D, Jochumsen K et al. Management of low-grade cervical cytology in young women: Cohort study from Denmark. Acta Oncologica. 2021;60(4):444-451. https://doi.org/10.1080/0284186X.2020.1831061

Author

St-Martin, Gry ; Thamsborg, Lise Holst ; Andersen, Berit ; Christensen, Jette ; Ejersbo, Dorthe ; Jochumsen, Kirsten ; Johansen, Tonje ; Larsen, Lise Grupe ; Waldstrøm, Marianne ; Lynge, Elsebeth. / Management of low-grade cervical cytology in young women : Cohort study from Denmark. In: Acta Oncologica. 2021 ; Vol. 60, No. 4. pp. 444-451.

Bibtex

@article{7ae9d00bd0cc44518bbd90f7bc360aba,
title = "Management of low-grade cervical cytology in young women: Cohort study from Denmark",
abstract = "Objective: Cytology findings of atypical squamous cells of unknown significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) are common among women under 30, but evidence on best management strategy is insufficient. We therefore investigated how different management strategies used in Denmark influenced biopsy rates and detection of cervical intraepithelial neoplasia (CIN). Methods: Register-based cohort study including Danish women aged less than 30 years and born 1980–95, with ASCUS/LSIL as their first abnormal cervical cytology in 2008–16. Rates and relative risks (RR) of biopsy and detection of CIN3+, CIN2 and < CIN2 during two years follow-up were compared between women referred directly to colposcopy after ASCUS/LSIL or undergoing additional testing, including mRNA or DNA test for high risk HPV or repeat cytology. Results: 19,946 women with ASCUS and 19,825 with LSIL were included in the study of whom 92% had adequate information about follow-up. Among women referred directly to biopsy, CIN3+ was detected among 21%, CIN2 in 17%, while 62% had < CIN2. Repeating cytology after 6 months reduced the biopsy rate to 44% of which 53% had < CIN2. Biopsy rates with HPV test were 67% for DNA test, 77% with 14-type mRNA test and 58% with 5-type mRNA test. The detection of CIN3+ was somewhat higher, between 13% and 14% for the three HPV tests vs. 11% with repeat cytology. However, the detection of < CIN2 (not indicating treatment) also increased with RR 2.11 (95% CI 2.01–2.21) for 14-type mRNA test, 1.35 (95% CI 1.29–1.41) for 5-type mRNA test, and 1.86 (95% CI 1.76–1.97) with HPV DNA test. Conclusions: The choice of management strategy influences both the detection rate for severe lesions (CIN3+) and the proportion of women followed up for potentially insignificant findings.",
keywords = "ASCUS, Cervical cancer screening, LSIL",
author = "Gry St-Martin and Thamsborg, {Lise Holst} and Berit Andersen and Jette Christensen and Dorthe Ejersbo and Kirsten Jochumsen and Tonje Johansen and Larsen, {Lise Grupe} and Marianne Waldstr{\o}m and Elsebeth Lynge",
year = "2021",
doi = "10.1080/0284186X.2020.1831061",
language = "English",
volume = "60",
pages = "444--451",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Taylor & Francis",
number = "4",

}

RIS

TY - JOUR

T1 - Management of low-grade cervical cytology in young women

T2 - Cohort study from Denmark

AU - St-Martin, Gry

AU - Thamsborg, Lise Holst

AU - Andersen, Berit

AU - Christensen, Jette

AU - Ejersbo, Dorthe

AU - Jochumsen, Kirsten

AU - Johansen, Tonje

AU - Larsen, Lise Grupe

AU - Waldstrøm, Marianne

AU - Lynge, Elsebeth

PY - 2021

Y1 - 2021

N2 - Objective: Cytology findings of atypical squamous cells of unknown significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) are common among women under 30, but evidence on best management strategy is insufficient. We therefore investigated how different management strategies used in Denmark influenced biopsy rates and detection of cervical intraepithelial neoplasia (CIN). Methods: Register-based cohort study including Danish women aged less than 30 years and born 1980–95, with ASCUS/LSIL as their first abnormal cervical cytology in 2008–16. Rates and relative risks (RR) of biopsy and detection of CIN3+, CIN2 and < CIN2 during two years follow-up were compared between women referred directly to colposcopy after ASCUS/LSIL or undergoing additional testing, including mRNA or DNA test for high risk HPV or repeat cytology. Results: 19,946 women with ASCUS and 19,825 with LSIL were included in the study of whom 92% had adequate information about follow-up. Among women referred directly to biopsy, CIN3+ was detected among 21%, CIN2 in 17%, while 62% had < CIN2. Repeating cytology after 6 months reduced the biopsy rate to 44% of which 53% had < CIN2. Biopsy rates with HPV test were 67% for DNA test, 77% with 14-type mRNA test and 58% with 5-type mRNA test. The detection of CIN3+ was somewhat higher, between 13% and 14% for the three HPV tests vs. 11% with repeat cytology. However, the detection of < CIN2 (not indicating treatment) also increased with RR 2.11 (95% CI 2.01–2.21) for 14-type mRNA test, 1.35 (95% CI 1.29–1.41) for 5-type mRNA test, and 1.86 (95% CI 1.76–1.97) with HPV DNA test. Conclusions: The choice of management strategy influences both the detection rate for severe lesions (CIN3+) and the proportion of women followed up for potentially insignificant findings.

AB - Objective: Cytology findings of atypical squamous cells of unknown significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) are common among women under 30, but evidence on best management strategy is insufficient. We therefore investigated how different management strategies used in Denmark influenced biopsy rates and detection of cervical intraepithelial neoplasia (CIN). Methods: Register-based cohort study including Danish women aged less than 30 years and born 1980–95, with ASCUS/LSIL as their first abnormal cervical cytology in 2008–16. Rates and relative risks (RR) of biopsy and detection of CIN3+, CIN2 and < CIN2 during two years follow-up were compared between women referred directly to colposcopy after ASCUS/LSIL or undergoing additional testing, including mRNA or DNA test for high risk HPV or repeat cytology. Results: 19,946 women with ASCUS and 19,825 with LSIL were included in the study of whom 92% had adequate information about follow-up. Among women referred directly to biopsy, CIN3+ was detected among 21%, CIN2 in 17%, while 62% had < CIN2. Repeating cytology after 6 months reduced the biopsy rate to 44% of which 53% had < CIN2. Biopsy rates with HPV test were 67% for DNA test, 77% with 14-type mRNA test and 58% with 5-type mRNA test. The detection of CIN3+ was somewhat higher, between 13% and 14% for the three HPV tests vs. 11% with repeat cytology. However, the detection of < CIN2 (not indicating treatment) also increased with RR 2.11 (95% CI 2.01–2.21) for 14-type mRNA test, 1.35 (95% CI 1.29–1.41) for 5-type mRNA test, and 1.86 (95% CI 1.76–1.97) with HPV DNA test. Conclusions: The choice of management strategy influences both the detection rate for severe lesions (CIN3+) and the proportion of women followed up for potentially insignificant findings.

KW - ASCUS

KW - Cervical cancer screening

KW - LSIL

U2 - 10.1080/0284186X.2020.1831061

DO - 10.1080/0284186X.2020.1831061

M3 - Journal article

C2 - 33030976

AN - SCOPUS:85092388895

VL - 60

SP - 444

EP - 451

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 4

ER -

ID: 250476414